Constitutive Activation of the Mitogen-Activated Protein Kinase Signaling Pathway in Acral Melanomas  by Takata, Minoru et al.
Constitutive Activation of the Mitogen-Activated Protein Kinase
Signaling Pathway in Acral Melanomas
Minoru Takata, Yasufumi Goto,1 Nami Ichii, Maki Yamaura, Hiroshi Murata, Hiroshi Koga,
Akihide Fujimoto,w and Toshiaki Saida
Department of Dermatology, Shinshu University School of Medicine, Matsumoto, Japan; wDepartment of Dermatology, Kanazawa University Graduate School of
Medical Science, Kanazawa, Japan
One of the most attractive clinical targets for melanoma is the mitogen-activated protein kinase (MAPK) signaling
pathway. In this study, we examined MAPK signaling activation in a total of 28 acral melanoma samples, consisting
of 13 primary tumors and 15 metastases. In line with the previous reports, NRAS/BRAF mutations were rare; only
one metastatic tumor had an NRAS E61R mutation, and one primary tumor and two metastases harbored BRAF
V599E mutations. Western blot analyses, however, revealed phosphorylated extracellular signal-regulated kinase
(ERK)1/2 proteins in 11 of 14 (78.5%) of the acral melanoma tumors. Furthermore, ﬂuorescence in situ hybridization
analyses revealed the prominent ampliﬁcation of the cyclin D1 (CCND1) gene, which is an important down-stream
effecter of the MAPK pathway, in 5 of 21 (23.8%) tumors examined. Interestingly, two of three tumors that were
negative for phosphorylated ERK proteins according to western blot harbored CCND1 ampliﬁcations, suggesting
that the increased gene dosage of CCND1 may exert effects similar to phosphorylated ERK proteins in cell growth.
We conclude that, despite the low frequency of BRAF/NRAS mutations, the MAPK signaling pathway is consti-
tutively activated in the majority of acral melanomas. This provides a rational basis to include acral melanomas into
the clinical trials with MAPK inhibitors.
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There are great ethnic variations in the incidence and the
anatomic distribution of cutaneous melanomas (Pathak
et al, 1982). Light-skinned Caucasians have a high inci-
dence of melanomas, and the majority of them occur on the
trunk and extremities, suggesting intermittent sun exposure
as a major pathogenetic factor (Elwood and Gallagher,
1998). According to a pathological classification of cutane-
ous melanomas (Clark et al, 1986), most of these me-
lanomas are of the superficial spreading type. In contrast, in
non-Caucasian populations such as the Japanese, the
overall incidence of melanomas is much lower, and more
than half of the melanomas are of the acral lentiginous type
that develop in relatively or completely sun-protected sites
such as the palms, soles, and nail beds (Ishihara et al,
2001). Although controversy remains as to whether the
clinicopathologic variations among cutaneous melanomas
reflect inherent biologic differences (McGovern, 1982), re-
cent molecular cytogenetic studies have shown clear dif-
ferences in the genetic make-up among the different
subtypes of melanomas (Bastian et al, 2000, 2003). This
may have significant clinical relevance, since potential ther-
apeutic targets might therefore vary among the different
melanoma types.
One of the most attractive clinical targets for melanoma
is the RAS–RAF-mitogen-activated protein kinase (MAPK)
signaling pathway (Sebolt-Leopold and Herrera, 2004). The
MAPK pathway plays a central role in regulating the growth
and survival of cells from a broad spectrum of human
tumors (Johnson and Lapadat, 2002) including melanoma
(Cohen et al, 2002; Govindarajan et al, 2003). In most Cau-
casian melanomas, extracellular signal-regulated kinase
(ERK)1 and ERK2, downstream effectors of this pathway,
were reported to be constitutively activated (Satyamoorthy
et al, 2003). The high constitutive ERK activity in melanoma
is most likely a consequence of mutations in upstream
components. Activating RAS mutations, most of which are
at codon 61 of NRAS, have been identified in 9%–15% of
melanomas (Albino et al, 1989; van ’t Veer et al, 1989; Ball
et al, 1994; van Elsas et al, 1996). Furthermore, one of the
RAF-family proteins, BRAF, is mutated in 60%–66% of me-
lanomas, with a single substitution (T ! A) of glutamate for
valine (V599E), being responsible for 92% of the observed
mutations (Davies et al, 2002). The incidence of NRAS/
BRAF mutations, however, is heavily dependent on the sun
exposure pattern of the primary tumor sites. NRAS muta-
tions were most frequently found in tumors from chronically
sun-exposed sites, whereas the highest BRAF mutation
rates were reported in intermittently sun-exposed sites (van
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Elsas et al, 1996; Jiveskog et al, 1998; Maldonado et al,
2003). By contrast, both RAS and BRAF mutations were
rare in melanomas on glabrous skin and mucous mem-
branes that are unexposed to sun (van Elsas et al, 1996;
Jiveskog et al, 1998; Maldonado et al, 2003; Edwards et al,
2004). Thus, whether or not these types of melanomas
arising in sun-protected sites show constitutive activation of
the MAPK pathway is not known and needs to be inves-
tigated. This is important because small-molecule inhibitors
such as BAY43-9006 designed to target the MAPK pathway
are now available and have entered clinical trials targeting
metastatic melanomas (Sebolt-Leopold and Herrera, 2004).
This study was aimed at investigating NRAS/BRAF muta-
tions and the MAPK signaling pathway activation in a series
of 28 Japanese acral melanomas. We also examined the
amplifications of the cyclin D1 gene (CCND1), which is an
important down-stream effecter of the MAPK pathway and
was reported to be amplified in nearly half of primary acral
melanomas (Sauter et al, 2002).
Results and Discussion
In a total of 28 acral melanoma samples consisting of 13
primary tumors and 15 metastases, one primary tumor and
two metastases harbored BRAF V599E mutations (Table I).
Although a minor proportion of BRAF mutations other than
V599E were detected in exons 11 and 15 (Brose et al, 2002;
Davies et al, 2002), we did not detect such mutations. The
overall frequency of BRAF mutations in our acral melanoma
Table I. NRAS/BRAF mutations, ERK phosphorylation, and CCND1 ampliﬁcation in acral melanomas












1 M 51 Sole Primary Wild type Wild type þ  
2 M 82 Sole Primary Wild type Wild type   þ
3 M 81 Finger nail Primary Wild type Wild type   
4 F 61 Toe Primary Wild type V599E þ  
5 M 69 Sole Primary Wild type Wild type NE  þ
6 F 38 Finger nail Primary Wild type Wild type NE  
7 F 74 Sole Primary Wild type Wild type NE  þ
8 F 86 Sole Primary Wild type Wild type NE  NE
9 M 77 Finger Primary Wild type Wild type NE þ NE
10 M 75 Toe Primary Wild type Wild type NE  
11 F 78 Sole Primary Wild type Wild type NE  
12 F 80 Toe nail Primary Wild type Wild type NE  
13 M 72 Sole Primary Wild type Wild type NE þ NE
14 M 79 Palm Metastasis Wild type Wild type þ  
15 M 80 Sole Metastasis E61R Wild type þ þ 
16 F 69 Sole Metastasis Wild type Wild type þ þ 
17 F 75 Finger Metastasis Wild type Wild type þ þ NE
18 M 57 Sole Metastasis Wild type Wild type þ þ 
19 M 35 Sole Metastasis Wild type Wild type   þ
20 M 74 Finger nail Metastasis Wild type Wild type þ  þ
21 F 76 Sole Metastasis Wild type Wild type þ  
22 F 81 Toe Metastasis Wild type Wild type þ þ 
23 M 77 Sole Metastasis Wild type Wild type þ  
24 M 75 Sole Metastasis Wild type V599E NE þ NE
25 F 44 Sole Metastasis Wild type V599E NE  
26 M 73 Sole Metastasis Wild type Wild type NE  NE
27 M 77 Sole Metastasis Wild type Wild type NE þ 
28 F 76 Finger Metastasis Wild type Wild type NE  NE
NE, not examined; ERK, extracellular signal-regulated kinase; CCND1, cyclin D1.
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samples was 10.7%, which is similar to the 15% (6 of 39)
incidence of primary acral melanomas reported previously
(Maldonado et al, 2003). Although a much higher incidence
of BRAF mutations was reported in metastatic than in pri-
mary lesions (Houben et al, 2004; Shinozaki et al, 2004),
only two of 15 (13.3%) acral melanoma metastases had
mutations. NRAS mutations were also rare; a CAA (Glu) to
CGA (Arg) mutation at codon 61 was detected in only one
metastasis (Table I). The result is consistent with the pre-
vious reports showing rare NRAS mutations in melanomas
arising from the mucous membrane or unexposed skin (van
Elsas et al, 1996; Jiveskog et al, 1998).
Despite the low frequency of NRAS/BRAF mutations,
western blot analyses revealed phosphorylated-ERK1/2
proteins in 11/14 (78.5%) of the acral melanoma tumors
(Table I and Fig 1). This result indicates that the MAPK
signaling pathway is constitutively activated in the majority
of acral melanomas without NRAS/BRAF mutations. Similar
results have already been reported in uveal melanomas.
Uveal melanomas had neither NRAS nor BRAF mutations,
but constitutive activation of the MAPK pathway was, re-
spectively, demonstrated in 50% (20 of 40) and 86% (36 of
42) of samples with western blot (Rimoldi et al, 2003) and
immunohistochemistry (Weber et al, 2003), suggesting that
neither NRAS nor BRAFmutations may be a prerequisite for
the activation of the MAPK signaling pathway. Several al-
ternative ways of activation of MAPK signaling have recently
been demonstrated, including autocrine growth factor stim-
ulation (Satyamoorthy et al, 2003), epigenetic inactivation
of RAS association domain family protein 1 (RASSF1A)
(Spugnardi et al, 2003), downregulation of an ERK signaling
inhibitor SPRY2 (Tsavachidou et al, 2004), loss or reduction
of RAF kinase inhibitory protein (PKIP) (Schuierer et al,
2004), and overexpression of wild-type BRAF in part as a
result of gene amplification (Tanami et al, 2004). Specific
pathways leading to constitutive activation of ERK without
BRAF mutations in acral melanomas remain to be estab-
lished.
It was noteworthy that there was a marked discrepancy
in the results detecting phosphorylated-ERK proteins be-
tween the western blot and immunohistochemistry (Table I).
Six of 11 tissues containing phosphorylated-ERK proteins
demonstrated by western blotting failed to exhibit immuno-
reactivity in the immunohistochemistry (Fig 2). The most
common problem encountered in the application of phos-
phorylation-specific antibodies to fixed tissue is a false-
negative reaction. This can be because of the inaccessibility
of the antigen to antibody, although we performed antigen
retrieval as recommended by the manufacturer. Another
possibility is the loss of phosphorylation sites during fixation
(Mandell, 2003). Our results raise the possible objections to
the use of immunohistochemistry for the detection of phos-
phorylated proteins in vivo unless appropriate positive and
negative controls are included.
In three of 14 frozen samples, western blotting did not
reveal phosphorylated-ERK proteins, suggesting that con-
stitutive activation of the MAPK pathway is not taking place
in these tumors (Table I and Fig 1). Interestingly, fluores-
cence in situ hybridization (FISH) analyses revealed the
prominent amplification of CCND1 in two of three phos-
phorylated-ERK-negative cases (cases 2 and 19) (Fig 3). A
primary tumor of case 5 also showed CCND1 amplification.
Although in vivo tissue sample for western blotting was not
available in this case, we established a cell line (SMYM-
PRGP) from this primary tumor. SMYM-PRGP also harbors
CCND1 amplification, and shows no expression of phos-
phorylated-ERK proteins by western blotting (H. Murata and
M. Takata, unpublished observations). Thus, most of the
acral melanoma tumors that lacked any evidence of con-
stitutive MAPK pathway activation seemed to harbor
CCND1 amplifications. Cyclin D1 protein is one of the im-
portant down-stream effectors of the MAPK pathway, and
the CCND1 promoter acts as a sensor for growth signals
conveyed via the MAPK cascade (Sherr, 2000). The impor-
tance of cyclin D1 in the cell growth of melanomas was
demonstrated using anti-sense treatment targeted at cyclin
D1 in melanoma cell lines (Sauter et al, 2002). It is possible,
therefore, that the increased gene dosage of CCND1 may
Figure 1
Analysis of the status of mitogen-activated protein kinase (MAPK)
signaling pathway proteins in acral melanoma samples in vivo.
Protein extracts from the indicated tumor samples were analyzed by
western blotting using anti-p42/p44 MAPK (extracellular signal-regu-
lated kinase (ERK)1/2) and anti-phosphorylated p42/p44 MAPK (phos-
phorylated ERK1/2) antibodies. b-actin serves as loading control.





vated protein kinase (MAPK) proteins
in acral melanomas. Paraffin-embedded
tissue sections were stained with phos-
pho-p44/42 MAPK antibody. (A) Nuclear
and cytoplasmic expression of phos-
phorylated-p44/42 MAPK in case 17. (B)
No staining in the case 14 tumor, although
western blot detected the expression of
phosphorylated-p44/42 MAPK in this tu-
mor. Scale bar: 50 mm.
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exert effects similar to phosphoryled-ERK proteins and
promote the growth of melanoma cells in these cases.
Because of the high incidence of NRAS/BRAF oncogenic
mutations in melanomas in the Caucasian population, clin-
ical trails with MAPK-pathway inhibitors for metastatic me-
lanoma have already started. A favorable response was
seen in a phase I trial of the RAF inhibitor BAY43-9006
against melanoma in combination with paclitaxel or car-
boplatin (Sebolt-Leopold and Herrera, 2004). The results
from this study, showing a high frequency of MAPK-path-
way activations in acral melanomas, provide a rational basis
to include this type of melanoma in such clinical trails with
MAPK inhibitors.
Materials and Methods
Tissues A total of 28 cases of acral melanoma (13 primary tumors
and 15 metastases) were included in this study (Table I). According
to their histology, all the primary tumors were of the acral lent-
iginous type. Paraffin-embedded tissues of these cases were re-
trieved from the archives of the Department of Dermatology,
Shinshu University Hospital, Matsumoto, Japan, and the Depart-
ment of Dermatology, Kanazawa University Hospital, Kanazawa,
Japan. Fresh-frozen tissues were also available for 14 tumors. This
study was conducted according to the Declaration of Helsinki
Principles, and written informed consents were obtained from the
patients. The medical ethical committee of the Shinshu University
School of Medicine approved this study.
Mutation analyses DNA was extracted from 10 mm paraffin-em-
bedded tissue sections using a MagneSil Genomic, Fixed Tissue
System (Promega, Madison, Wisconsin). To detect the NRAS/
BRAF mutations, NRAS exon 2 and BRAF exons 11 and 15 were
PCR amplified as described previously (Davies et al, 2002; Cruz
et al, 2003). Because of the frequent dropouts not yielding desired
PCR products, we also used the nested-PCR approach for the ampli-
fication of NRAS exon 2 (Houben et al, 2004). PCR amplicons were
purified with QIAquick (Qiagen, Valencia, California), and directly
sequenced using Big Dye Terminator sequencing chemistry (Ap-
plied Biosystems, Foster City, California) and an ABI automated
sequencer (Applied Biosystems). When a low mutant peak was ob-
served overlapping with a wild-type peak at nucleotide positions of
the reported mutation sites, the samples were also sequenced in
reverse direction to confirm the presence or absence of the mutation.
Western blotting Fresh-frozen tumor samples were lysed in a
Tris-HCl buffer containing protease inhibitor cocktail (Roche, Man-
nheim, Germany), NP-40, Na3VO4, dithiothreitol, EGTA, NaF, and b-
glycerophosphate (Wako Kagaku Industry, Osaka, Japan). Protein
concentrations were determined by Coomassie brilliant blue stain-
ing. Lysates were subjected to SDS-PAGE under non-reducing
conditions. The separated proteins were transferred on to a PVDF
membrane (Bio-Rad Laboratories, Hercules, California). We de-
tected the phosphorylated-p44/42 MAPK protein and p44/42
MAPK protein using a PhosphoPlus p44/42 Kinase Antibody Kit
(Cell Signaling Technology, Beverly, Massachusetts). Mouse mono-
clonal anti-b-actin antibody (Abcam, Cambridge, Massachusetts)
was used as loading control. Immunoreactivity was detected using
a FluorImager 575 (Bio-Rad Laboratories).
Immunohistochemistry Four micron thick paraffin-embedded
tissue sections were stained with phospho-p44/42 MAP kinase
(Thy202/Try204) antibody #9101 using a SignalStain Phospho-p44/
42 IHC Detection Kit (Cell Signaling Technology). Prior to staining,
antigen unmasking was performed by boiling the slides for 10 min
in 0.01 M sodium citrate buffer (pH 6.0). Pre-diluted negative con-
trol was included in the kit. Nuclear staining in 410% of tumor
cells was regarded as positive.
FISH Amplification of the CCND1 was examined in the paraffin-
embedded tissue sections with a dual-color FISH technique. A
dual-color probe mixture consisting of a Spectrum Orange LSI
Cyclin D1 probe (band region 11q13) and Spectrum Green CEP 11
(band region 11p–11.11–q11, locus D11Z1) was purchased from
Vysis (Downers Grove, Illinois). The staining was performed fol-
lowing the manufacturer’s protocol. Briefly, paraffin-embedded tis-
sues were cut into 4 mm sections and mounted on silanized slides
(DAKO, Carpinteria, California). After deparaffinization, pre-treat-
ment was performed using a Paraffin Pretreatment Reagent Kit
(Vysis). Hybridization was carried out for 15 h at 371C, and then
slides were washed once in post-hybridization washing buffer
(2  SSC, 0.3% NP-40) at room temperature, followed by a rinse in
post-hybridization washing buffer at 721C for 2 min. Sections were
then counterstained with 4,6-diamino-2-phenylindole (Vysis). FISH
signals were scored with a fluorescent microscope (Carl Zeiss,
OberKochen, Germany) equipped with a triple band-pass filter.
Three-color images were captured by using a digital imaging anal-
ysis system. Copy numbers of CEP11 (green) and CD1 signals (or-
ange) were, respectively, counted for more than 50 non-overlapping
tumor cells. The tumor was determined to have CCND1 amplifica-
tion when there were 42.5-fold more test probe signals than ref-
erence signals in at least 30% of the tumor cells (Sauter et al, 2002).
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Figure 3
Fluorescence in situ hybridization (FISH)
showing clustered cyclin D1 (CCND1) am-
plification in a phosphorylated-p44/42 mi-
togen-activated protein kinase (MAPK)-
negative acral melanoma metastasis (A)
and no CCND1 amplification in a phos-
phorylated-p44/42 MAPK-positive metas-
tasis (B). Dual-color FISH was performed
on paraffinsections. Red signals, CCND1
probe; green signals, CEP 11 probe. (A)
Case 19; (B) case 22.
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